Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Slides:

Advertisements

Similar presentations

CC Chemokine Receptor 5 and CXC Chemokine Receptor 6 Expression by Lung CD8+ Cells Correlates with Chronic Obstructive Pulmonary Disease Severity Christine.

Advertisements

Telomerase Activity and Expression of Telomerase RNA Component and Telomerase Catalytic Subunit Gene in Cervical Cancer Kenji Nakano, Elizabeth Watney,

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar The.

Socializing Individualized T-Cell Cancer Immunotherapy

Volume 20, Issue 2, (February 2012)

Production and clinical development of nanoparticles for gene delivery

414. A Novel Clinical Severity Scoring Measure in Canine X-Linked Myotubular Myopathy: Results Following Systemic AAV Gene Replacement Molecular Therapy

209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.

446. Gender Differences in the Osteogenic & Chondrogenic Potential of Human Muscle- Derived Stem Cells In Vitro Alex C. Scibetta, Andrea B. Liebowitz,

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Genome-editing Technologies for Gene and Cell Therapy

627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase Molecular Therapy Volume.

Will Engineered T Cells Expressing CD20 scFv Eradicate Melanoma?

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Volume 24, Issue 11, Pages (November 2016)

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy Molecular Therapy Volume.

Scratching the Surface of Immunotherapeutic Targets in Neuroblastoma

Eun-Jung Jung, George A. Calin Cancer Cell

Direct Conversion of Skin Cells into Blood: Alchemy or Science?

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

Evolving Gene Therapy in Primary Immunodeficiency

Volume 20, Issue 6, Pages (June 2012)

343. Benchtop DNA Synthesizer: Oligo-Templated Polymerization (OTP)

Patrick R. Murray The Journal of Molecular Diagnostics

Circulating tumor DNA: Solid data from liquid biopsies

Escaping the Valley of Death

Volume 26, Issue 2, Pages (February 2018)

HIV Receives a “One Two Knockout Punch”

Xiuyan Wang, Isabelle Rivière Molecular Therapy - Oncolytics

A Theranostic “SMART” Aptamer for Targeted Therapy of Prostate Cancer

The Other Face of Chimeric Antigen Receptors

724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.

Volume 130, Issue 6, (September 2007)

Genome-editing Technologies for Gene and Cell Therapy

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

Premal Lulla, Carlos A. Ramos Molecular Therapy

The Pharmacology of T Cell Therapies

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Designer Lipids Advance Systemic siRNA Delivery

Volume 20, Issue 6, Pages (June 2012)

133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy Molecular.

660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy Geeta Shroff Molecular Therapy

Volume 26, Issue 2, Pages (February 2018)

68. Site Specific Intra-Placental Gene Transfer Corrects Fetal Growth Restriction in a Novel Mouse Model of Placental Insufficiency (PI) Molecular.

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement Molecular.

Volume 26, Issue 4, Pages (April 2018)

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Chimeric antigen receptor T-cell therapy for solid tumors

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Chimeric Antigen Receptor–Modified T Cells: Clinical Translation in Stem Cell Transplantation and Beyond Stanley R. Riddell, Michael C. Jensen, Carl.

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency Molecular.

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Gregory G. Ginsberg, MD Gastrointestinal Endoscopy

773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Shigeki Yagyu, Malcolm K. Brenner

History of Oncolytic Viruses: Genesis to Genetic Engineering

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Volume 134, Issue 6, (September 2008)

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Shirley Wong, Roderick A. Slavcev

A Review of First-Line Treatment for Small-cell Lung Cancer

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen Gottschalk Molecular Therapy Volume 24, Issue 9, Pages 1511-1512 (September 2016) DOI: 10.1038/mt.2016.173 Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 Naturally occurring cancers in dogs can facilitate the development of CAR T-cell therapies for cancer. Evaluating cell therapies (Potential Therapy) not only in vitro and murine models, but also in canines holds the promise to improve our ability to select the optimal cell product prior to performing clinical studies in humans. Molecular Therapy 2016 24, 1511-1512DOI: (10.1038/mt.2016.173) Copyright © 2016 American Society of Gene & Cell Therapy Terms and Conditions